Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.

Autor: Ahmadi SE; Departments of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran., Shabannezhad A; Departments of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran., Kahrizi A; Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Akbar A; Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Safdari SM; Departments of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran., Hoseinnezhad T; Department of Hematolog, Faculty of Allied Medicine, Bushehr University of Medical Sciences, Bushehr, Iran., Zahedi M; Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran., Sadeghi S; Faculty of Science, Engineering and Computing, Kingston University, London, UK., Mojarrad MG; Shahid Beheshti Educational and Medical Center, Kashan University of Medical Sciences, Kashan, Iran., Safa M; Departments of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran. majidsafa@gmail.com.
Jazyk: angličtina
Zdroj: Biomarker research [Biomark Res] 2023 Jun 06; Vol. 11 (1), pp. 60. Date of Electronic Publication: 2023 Jun 06.
DOI: 10.1186/s40364-023-00504-6
Abstrakt: Tissue factor (TF) is a protein that plays a critical role in blood clotting, but recent research has also shown its involvement in cancer development and progression. Herein, we provide an overview of the structure of TF and its involvement in signaling pathways that promote cancer cell proliferation and survival, such as the PI3K/AKT and MAPK pathways. TF overexpression is associated with increased tumor aggressiveness and poor prognosis in various cancers. The review also explores TF's role in promoting cancer cell metastasis, angiogenesis, and venous thromboembolism (VTE). Of note, various TF-targeted therapies, including monoclonal antibodies, small molecule inhibitors, and immunotherapies have been developed, and preclinical and clinical studies demonstrating the efficacy of these therapies in various cancer types are now being evaluated. The potential for re-targeting TF toward cancer cells using TF-conjugated nanoparticles, which have shown promising results in preclinical studies is another intriguing approach in the path of cancer treatment. Although there are still many challenges, TF could possibly be a potential molecule to be used for further cancer therapy as some TF-targeted therapies like Seagen and Genmab's tisotumab vedotin have gained FDA approval for treatment of cervical cancer. Overall, based on the overviewed studies, this review article provides an in-depth overview of the crucial role that TF plays in cancer development and progression, and emphasizes the potential of TF-targeted and re-targeted therapies as potential approaches for the treatment of cancer.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: